Fig. 2
Metabolic tumor response to 37.5 mg daily sunitinib over time as measured with FDG-PET. Graphs illustrating the percent change in FDG SUVmax from pre-treatment baseline to after 1 (a), 2 (b), 3 (c), or 4 (d) weeks of sunitinib therapy in individual patients. There was a delayed metabolic response to continuous lower-dose sunitinib beginning after two weeks of treatment that was maintained throughout the duration of this study. Green bars represent metabolic response (≥25 % decrease in FDG SUVmax), red bars represent metabolic progression (≥25 % increase in FDG SUVmax), and blue bars represent stable disease (<25 % change in SUVmax). The bars are labeled with the corresponding patient study identification number